ES2145996T3 - Piridinas sustituidas con 3,4-diarilo para el tratamiento de la inflamacion. - Google Patents

Piridinas sustituidas con 3,4-diarilo para el tratamiento de la inflamacion.

Info

Publication number
ES2145996T3
ES2145996T3 ES96903715T ES96903715T ES2145996T3 ES 2145996 T3 ES2145996 T3 ES 2145996T3 ES 96903715 T ES96903715 T ES 96903715T ES 96903715 T ES96903715 T ES 96903715T ES 2145996 T3 ES2145996 T3 ES 2145996T3
Authority
ES
Spain
Prior art keywords
inflammation
substituted
piridines
diaryl
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96903715T
Other languages
English (en)
Inventor
Len F Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23527293&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2145996(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GD Searle LLC filed Critical GD Searle LLC
Application granted granted Critical
Publication of ES2145996T3 publication Critical patent/ES2145996T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE DESCRIBE UNA CLASE DE COMPUESTOS PIRIDIL SUSTITUIDOS PARA EL TRATAMIENTO DE LA INFLAMACION Y DE LOS TRASTORNOS RELACIONADOS CON LA INFLAMACION. LOS COMPUESTOS DE PARTICULAR INTERES SE DEFINEN POR LA FORMULA (I), DONDE R{SUP,1} ES HALOALQUILO; DONDE R{SUP,2} ES ARILO OPCIONALMENTE SUSTITUIDO EN UNA POSICION SUSTITUIBLE CON UNO O MAS RADICALES INDEPENDIENTEMENTE SELECCIONADOS A PARTIR DE ALQUIL ARBOXILO, ALCOXICARBONILO, HALOALQUILO, HIDROXILO, HIDROXIALQUILO, HALOALCOXI, AMINO, ALQUILAMINO, ARILAMINO, NITRO, HALO, ALCOXI Y ALQUILTIO; DONDE R{SUP,3} ES ARIL SUSTITUIDO EN UNA POSICION SUSTITUIBLE CON UN RADICAL SELECCIONADO A PARTIR DE ALQUILSULFONILO Y SULFAMILO; Y DONDE R{SUP,4} SE SELECCIONA DE ENTRE HALO, ALCOXI Y ALQUINILOXI; O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LOS MISMOS.
ES96903715T 1995-02-10 1996-02-08 Piridinas sustituidas con 3,4-diarilo para el tratamiento de la inflamacion. Expired - Lifetime ES2145996T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/386,843 US5596008A (en) 1995-02-10 1995-02-10 3,4-Diaryl substituted pyridines for the treatment of inflammation

Publications (1)

Publication Number Publication Date
ES2145996T3 true ES2145996T3 (es) 2000-07-16

Family

ID=23527293

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96903715T Expired - Lifetime ES2145996T3 (es) 1995-02-10 1996-02-08 Piridinas sustituidas con 3,4-diarilo para el tratamiento de la inflamacion.

Country Status (10)

Country Link
US (1) US5596008A (es)
EP (1) EP0808305B1 (es)
AT (1) ATE192436T1 (es)
AU (1) AU4770796A (es)
DE (1) DE69608096T2 (es)
DK (1) DK0808305T3 (es)
ES (1) ES2145996T3 (es)
GR (1) GR3033428T3 (es)
PT (1) PT808305E (es)
WO (1) WO1996024585A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW527186B (en) * 1996-03-19 2003-04-11 Janssen Pharmaceutica Nv Fused imidazole derivatives as multidrug resistance modulators
IT1288123B1 (it) * 1996-09-04 1998-09-10 Nicox Sa Uso di nitroderivati per l'incontinenza urinaria
DE69729946T2 (de) 1996-10-15 2005-01-20 G.D. Searle Llc Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia
US6525053B1 (en) 1997-08-22 2003-02-25 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
US6307047B1 (en) 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US7041694B1 (en) 1997-12-17 2006-05-09 Cornell Research Foundation, Inc. Cyclooxygenase-2 inhibition
US6649645B1 (en) * 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
US7141673B1 (en) 1999-01-14 2006-11-28 Lonza Ag 1-(6-methylpyridine-3-yl)-2-[4-(methylsulphonyl) phenyl] ethanone and method for its preparation
IL143981A0 (en) * 1999-01-14 2002-04-21 Lonza Ag 1-(6-methylpyridine-3-yl)-2-[4-(methylsulfonyl) phenyl) ethanone and method for its preparation
KR100793668B1 (ko) * 1999-12-08 2008-01-10 파마시아 코포레이션 강화된 생체이용률을 지닌 고체상 형태의 셀레콕시브
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
JP2004503601A (ja) * 2000-07-13 2004-02-05 ファルマシア・コーポレーション 眼のｃｏｘ−２媒介疾患の処置及び予防におけるｃｏｘ−２阻害剤の使用法
GB0021494D0 (en) 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
PE20021017A1 (es) 2001-04-03 2002-11-24 Pharmacia Corp Composicion parenteral reconstituible
US6673818B2 (en) 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
GB0112802D0 (en) 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
GB0112810D0 (en) 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
GB0119477D0 (en) 2001-08-09 2001-10-03 Glaxo Group Ltd Pyrimidine derivatives
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
US7329401B2 (en) 2002-04-15 2008-02-12 The Regents Of The University Of California Cyclooxygenase-2 selective agents useful as imaging probes and related methods
ATE325115T1 (de) 2002-08-19 2006-06-15 Glaxo Group Ltd Pyrimidinderivate als selektive cox-2-inhibitoren
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
AU2003303041B2 (en) 2002-12-13 2008-07-24 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
ES2275218T3 (es) 2003-05-07 2007-06-01 Osteologix A/S Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos.
WO2005044227A1 (en) * 2003-11-05 2005-05-19 Glenmark Pharmaceuticals Limited Topical pharmaceutical compositions
US20050100594A1 (en) * 2003-11-12 2005-05-12 Nilendu Sen Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor
BRPI0506994A (pt) 2004-01-22 2007-07-03 Pfizer derivados de triazol que inibem a atividade antagonista da vasopressina
US7429667B2 (en) * 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
TW200716594A (en) * 2005-04-18 2007-05-01 Neurogen Corp Substituted heteroaryl CB1 antagonists
EP1767161A1 (en) * 2005-09-22 2007-03-28 Zimmer Spine, Inc. Spinal fixation rod contouring system
PL1973884T3 (pl) * 2006-01-19 2017-05-31 Orchid Pharma Limited Nowe związki heterocykliczne
US7842836B2 (en) 2006-04-11 2010-11-30 Ardea Biosciences N-aryl-N'alkyl sulfamides as MEK inhibitors
JP5269762B2 (ja) * 2006-04-18 2013-08-21 アーディア・バイオサイエンシーズ・インコーポレイテッド Ｍｅｋ阻害剤としてのピリドンスルホンアミドおよびピリドンスルファミド
WO2008033466A2 (en) * 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
CA2673545A1 (en) 2006-12-22 2008-07-03 Recordati Ireland Limited Combination therapy of lower urinary tract disorders with .alpha.2.delta. ligands and nsaids
EP2114461A2 (en) * 2007-01-19 2009-11-11 Mallinckrodt Inc. Diagnostic and therapeutic cyclooxygenase-2 binding ligands
US8509487B2 (en) * 2007-04-19 2013-08-13 Avago Technologies General Ip (Singapore) Pte. Ltd. System and method for optically measuring a parameter of an object
US8563594B2 (en) 2007-05-08 2013-10-22 Allergan, Inc. S1P3 receptor inhibitors for treating pain
US11583516B2 (en) 2016-09-07 2023-02-21 Trustees Of Tufts College Dash inhibitors, and uses related thereto

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6816241A (es) * 1967-12-01 1969-06-03
US3655679A (en) * 1969-06-25 1972-04-11 Merck & Co Inc Certain aryl pyridine carboxylic acid derivatives
FR2248027B2 (es) * 1973-10-18 1977-09-09 Serdex
US5169857A (en) * 1988-01-20 1992-12-08 Bayer Aktiengesellschaft 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis
US5004743A (en) * 1987-11-25 1991-04-02 Merck Frosst Canada, Inc. Pyridyl styrene dialkanoic acids as anti-leukotriene agents
US5593994A (en) * 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors

Also Published As

Publication number Publication date
ATE192436T1 (de) 2000-05-15
US5596008A (en) 1997-01-21
EP0808305B1 (en) 2000-05-03
DE69608096T2 (de) 2000-11-02
EP0808305A1 (en) 1997-11-26
DK0808305T3 (da) 2000-08-28
AU4770796A (en) 1996-08-27
GR3033428T3 (en) 2000-09-29
PT808305E (pt) 2000-10-31
DE69608096D1 (de) 2000-06-08
WO1996024585A1 (en) 1996-08-15

Similar Documents

Publication Publication Date Title
ES2145996T3 (es) Piridinas sustituidas con 3,4-diarilo para el tratamiento de la inflamacion.
DE69425442D1 (de) 1,3,5- trisubstituierte pyrazolverbindungen zur behandlung von entzündungen
DK0808304T3 (da) 2,3-substituerede pyridiner til behandling af inflammation
PT772601E (pt) Compostos imidazolilo 4,5-substituidos para o tratamento da inflamacao
CA2212836A1 (en) Substituted isoxazoles for the treatment of inflammation
EP1528059A3 (en) Substituted isoxazoles for the treatment of inflammation
DK0731795T3 (da) Substituerede pyrazolylbenzensulfonamider til behandling af inflammation
NZ332762A (en) Isobutylgaba and its derivatives for the treatment of pain
AU4284196A (en) Substituted biphenyl compounds for the treatment of inflammation
DK0833839T3 (da) Heterocykliske peptidylforbindelser, der er nyttige til behandling af thrombinrelaterede sygdomme
AU560579B2 (en) N-aromatic-n:-cycloalkylalkanoyl-piperazines
FI935360A0 (fi) Guanidinalkyl-1,1-bifosfonsyraderivat, foerfarande foer deras framstaellning samt deras anvaendning
UA35550C2 (uk) Похідні урацилу, що проявляють гербіцидну активність
NZ308398A (en) 2-amino benzoxazin-4-one derivatives and medicaments
TW221690B (es)
DK0824539T3 (da) Dialkyltiacumicin-forbindelser
ID24231A (id) Derivat-derivat 5-disubstitusi-1,2,4-tiadiazolil yang menghambat angiogenesis
MX9303605A (es) Derivados de azabicicloheptano n-substituidas, su obtencion y uso.
EP0712411A1 (en) ANTIPARASITIC AGENT
DK0558104T3 (da) 1,5-Benzodiazepinderivater og deres anvendelse i lægemidler
EP0811620A4 (en) PHENYLAMIDINOTHIOPHENE DERIVATIVES AND ANTIPHLOGISTIC AGENT CONTAINING THEM

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 808305

Country of ref document: ES